NCT06017557 (PREDAtOOR) is a NA clinical trial of Artificial Intelligence in Ovarian Cancer Stage III, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT06017557?

NCT06017557 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT06017557?

Interventions in NCT06017557: Artificial Intelligence.

What condition does NCT06017557 study?

NCT06017557 studies Ovarian Cancer Stage III, Ovarian Cancer Stage IV.

Is NCT06017557 still recruiting?

NCT06017557 is currently recruiting now. Last updated 19 December 2025.

Last reviewed 2025-12-19 · How we verify

NCT06017557: PREDAtOOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer

Recruiting now NA Last updated 19 December 2025

What this trial tests

NA trial testing Artificial Intelligence in Ovarian Cancer Stage III in 151 participants. Currently enrolling.

Timeline

2 January 2023

Primary endpoint
15 December 2025

1 September 2026

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	151
Start date	2 January 2023
Primary completion	15 December 2025
Estimated completion	1 September 2026
Sites	1 location across Italy

Drugs / interventions tested

Artificial Intelligence

Conditions studied

Ovarian Cancer Stage III — all drugs for Ovarian Cancer Stage III →
Ovarian Cancer Stage IV — all drugs for Ovarian Cancer Stage IV →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, female only, with Ovarian Cancer Stage III or Ovarian Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Application of ultrasound in combination with other methods in gynecological disease: artificial intelligence, surgery, and drugs.
Shi S, Dai C, Liu D, Liu X. · · 2025 · PMID 40958876 · DOI 10.3389/fonc.2025.1567024

Verify or expand the search:

Other trials of Artificial Intelligence

Trials testing the same drug.

NCT07189520 — 1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestin · not yet recruiting
NCT07265154 — Gait Training and Artificial Intelligence · NA · recruiting
NCT06770985 — Effectiveness of Artificial Intelligence Algorithms · completed
NCT06839261 — Evaluation of Double Lumen Tube Intubation Difficulty With Photo-Based Artificial Intelligence Algorithms · completed
NCT06517082 — Ambient AI for Provider Well-Being · NA · completed

Other recruiting trials for Ovarian Cancer Stage III

Currently open trials in the same condition.

NCT04701645 — Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer · Phase 1 · recruiting
NCT04997096 — Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera · NA · recruiting
NCT04938583 — Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer · Phase 1, PHASE2 · active not recruiting
NCT04789694 — Prehabilitation in Gynaecological Cancer Patients · Phase 3 · recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06017557 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 19 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06017557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing